Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.46 |
| ▸ | FEN1 | P39748 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521876 | 1.00 | BCAT2 (0.53) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL31227852 | 1.00 | BCAT2 (0.53) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| Trifluoroacetic Acid SCHEMBL3676572 | 0.90 | BCAT2 (0.47) | BCAT2CSNK1A1TYRO3DYRK1BGRM5 | |
| SCHEMBL27870881 | 0.86 | HCRTR2 (0.42) | ALOX5APFEN1ADRA1ATSHRMEN1 | |
| SCHEMBL28532968 | 0.85 | KDM4C (0.48) | TSHRKMT2ATDP1KDM4EHCRTR1 | |
| SCHEMBL30227102 | 0.85 | KDM4C (0.48) | TSHRKMT2ATDP1KDM4EHCRTR1 | |
| SCHEMBL30776208 | 0.85 | KDM4C (0.48) | TSHRKMT2ATDP1KDM4EHCRTR1 | |
| SCHEMBL30776205 | 0.85 | KDM4C (0.48) | TSHRKMT2ATDP1KDM4EHCRTR1 | |
| SCHEMBL19604229 | 0.83 | KDM4C (0.57) | CSNK1A1TYRO3DYRK1BGRM5ALOX5AP | |
| SCHEMBL3646683 | 0.81 | ADORA3 (0.47) | BCAT2CSNK1A1DYRK1BADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106083821-B | 3,5- of one kind, bis- substitutions-pyrazine -2- benzamide compound synthetic method | 上海皓元生物医药科技有限公司 | 2019-01-11 | — | — | CN | claimed |
| CN-107235867-A | It is used as the aryl sultam derivative of RORc conditioning agents | 弗·哈夫曼-拉罗切有限公司 | 2017-10-10 | — | — | CN | claimed |
| CN-104470917-B | Aryl sultam derivatives as RORc modulators | 弗·哈夫曼-拉罗切有限公司 | 2017-08-04 | — | — | CN | claimed |
| CN-104470917-A | Aryl sultam derivatives as RORc modulators | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | claimed |
| CN-103038235-A | Substituted imidazopyrazines | Bayer Pharma AG | 2013-04-10 | — | — | CN | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | claimed |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| CN-115768757-A | CD206 modulators and uses and methods of making thereof | 美利坚合众国,由健康及人类服务部部长代表 | 2023-03-07 | — | — | CN | disclosed |
| EP-3433237-A1 | CRYSTALLINE FORM | Astrazeneca AB (SE) | 2019-01-30 | — | — | EP | disclosed |
| CN-106083821-B | 3,5- of one kind, bis- substitutions-pyrazine -2- benzamide compound synthetic method | 上海皓元生物医药科技有限公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-106083821-B | 3,5- of one kind, bis- substitutions-pyrazine -2- benzamide compound synthetic method | 上海皓元生物医药科技有限公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-108658876-A | The chloro- N- of 3,5- diamino -6- (N- (4- phenyl butyls) carbonamidine base) pyrazine -2- benzamide compounds | 帕里昂科学公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| CN-101076331-A | Compositions comprising nicotinic acid receptor partial agonists for the treatment of rubeosis and lipid-related disorders | ARENA PHARM INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1809554-A | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | BCAT2 870/4885CSNK1A1 1250/4885TYRO3 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.